Trial Profile
A randomized, double-blind, placebo controlled, four-period, cross-over study to evaluate the cognitive effects of single oral administration of roflumilast in age-associated memory impairment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2022
Price :
$35
*
At a glance
- Drugs Roflumilast (Primary)
- Indications Memory disorders
- Focus Therapeutic Use
- Sponsors Takeda Pharma
- 26 May 2017 New trial record